Discover a study that found that abobotulinum toxin A and prabotulinum toxin A demonstrated the quickest onset of action.

Hailing from South Korea, Letybo is the sixth and most recent neuromodulator approved by the FDA. Here, dermatologists unpack ...

Myoxinol fits into a wider trend of using neuropeptides in skincare, which aim to modulate nerve signalling or muscle ...

These findings suggest that temporary suppression of AF inducibility was achieved with botulinum toxin in this canine model, and this might be associated with reduced dispersion of ERP. Although the ...

In a comprehensive research study, scientists have uncovered a previously unknown mechanism explaining how neurons survive botulinum neurotoxin type A (BoNT/A) exposure, despite the toxin's ...

What mechanism allows neurons to remain alive while their function is blocked? This question has puzzled researchers since botulinum toxin was first developed for medical use. The current study ...

This includes increasing the duration of action for Botulinum Toxin Type A, which has been an important innovation. Besides, increased healthcare spending in emerging markets is a major driving ...

Among patients with chronic low back pain, botulinum neurotoxin type A demonstrated a favorable effect on pain reduction and functional improvement compared with control treatments. Botulinum ...

This would be Dermata's second patent for DMT410, if issued, using its Spongilla technology to topically deliver botulinum toxin for hyperhidrosis ... freshwater sponge with multiple unique mechanisms ...

However, this surge has revealed a troubling trend: the illegal distribution of unapproved botulinum toxin products ... regulations and enforcement mechanisms are crucial to ensure that unapproved ...